Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSL Of Australia Gets U.S. FDA Panel Backing For Blood Disorder Drug

This article was originally published in PharmAsia News

Executive Summary

Australia's CSL won unanimous approval of a U.S. FDA advisory panel judging the safety of its Riastap plasma-based drug for treating congenital fibrinogen deficiency. The panelists recommended approval based on the drug's success in boosting a clotting protein associated with the rare blood disorder. They noted limited testing of the therapy, but the head of U.S. research and development said CSL plans to gather more data in post-market studies. The agency is expected to decide by Jan. 17. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts